Estimation of tumor control probability model parameters from 3-D dose distributions of non-small cell lung cancer patients

• Published in: Lung cancer (Amsterdam, Netherlands) Vol. 24; no. 1; pp. 31 - 37
• Main Authors: Martel, Mary Kaye, Ten Haken, Randall K, Hazuka, Mark B, Kessler, Marc L, Strawderman, Myla, Turrisi, Andrew T, Lawrence, Theodore S, Fraass, Benedick A, Lichter, Allen S
• Format: Journal Article
• Language: English
• Published: Shannon Elsevier Ireland Ltd 01.04.1999; Elsevier Science
• Subjects: Biological and medical sciences; Carcinoma, Non-Small-Cell Lung - radiotherapy; Disease-Free Survival; Diseases of the respiratory system; Dose-Response Relationship, Radiation; Dose–volume histogram; Humans; Local control; Lung Neoplasms - radiotherapy; Medical sciences; Models, Theoretical; Non-small cell lung cancer; Radiation Dosage; Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects); Retrospective Studies; Three-dimensional treatment planning; Tumor control probability; Three-dimensional treatment planning; Tumor control probability; Local control; Dose–volume histogram; Non-small cell lung cancer; Dose repartition; Lung disease; Histogram; Respiratory disease; Malignant tumor; Three dimensional field; Radiotherapy; Bronchopulmonary; Dose activity relation; Treatment; Bronchus disease; Mathematical model; Response probability; Non small cell carcinoma
• ISSN: 0169-5002; 1872-8332
• DOI: 10.1016/S0169-5002(99)00019-7

Tumor control probability (TCP) model calculations may be used in a relative manner to evaluate and optimize three-dimensional (3-D) treatment plans. Using a mathematical model which makes a number of simplistic assumptions, TCPs can be estimated from a 3-D dose distribution of the tumor given the dose required for a 50% probability of tumor control ( D 50) and the normalized slope ( γ) of the sigmoid-shaped dose–response curve at D 50. The purpose of this work was to derive D 50 and γ from our clinical experience using 3-D treatment planning to treat non-small cell lung cancer (NSCLC) patients. Our results suggest that for NSCLC patients, the dose to achieve significant probability of tumor control may be large (on the order of 84 Gy) for longer (>30 months) local progression-free survival.